Skip to main content
. 2020 Apr;8(8):542. doi: 10.21037/atm.2020.02.125

Figure 4.

Figure 4

Objective response rate of TACE plus apatinib compared to TACE monotherapy in intermediate- to advanced-stage HCC patients. TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma.